Ozempic and Bupropion Interaction: Safety, Mechanisms, and Clinical Guidance
HealthRX.com
No described interaction between Ozempic and bupropion
Key numbers
- 0.4%Seizure risk with immediate-release bupropion at 300 to 450 mg/day (13 of 3,200 patients)Source: accessdata.fda.gov, as cited Nov 7, 2026
- 29.8%Symptomatic low glucose on Ozempic 1 mg with basal insulin, versus 15.2% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 20.3%Nausea in type 2 diabetes trials on Ozempic 1 mg, versus 6.1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
FDA adverse event reports listing both bupropion and semaglutide
Through 2026-10-28, FDA had received 1,616 adverse event reports that list both bupropion and semaglutide, out of 112,512 reports for bupropion and 111,027 for semaglutide. A joint report shows both were recorded for the same person, not that they interacted.
| Measure | Value |
|---|---|
| Reports listing both drugs | 1,616 |
| All reports for bupropion | 112,512 |
| All reports for semaglutide | 111,027 |
| Joint reports naming nausea | 318 |
| Joint reports naming vomiting | 221 |
| Joint reports naming diarrhoea | 181 |
| Joint reports naming impaired gastric emptying | 166 |
How this was calculated
Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.
Reports listing both bupropion and semaglutide as single-ingredient active substances, any brand, suspect or concomitant
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.
From the public record
Published papers mentioning both semaglutide and bupropion
PubMed indexes 130 papers whose title or abstract mentions both semaglutide and bupropion, 97 of them published from 2016 to 2025. For comparison, 5,897 papers mention semaglutide and 5,784 mention bupropion.
| Measure | Value |
|---|---|
| Papers mentioning both | 130 |
| Of those, published 2016 to 2025 | 97 |
| Papers mentioning semaglutide | 5,897 |
| Papers mentioning bupropion | 5,784 |
How this was calculated
Ran one PubMed title and abstract search requiring both names, and one search for each name alone. No filtering by study type or quality.
PubMed records naming both substances in the title or abstract, all article types and species
A paper that mentions both is not necessarily a study of their interaction, and may report no interaction. Counts include animal, cell and review papers.
At a glance
- Direct interaction / Not described in the Ozempic or Contrave labels [1][3]
- Semaglutide metabolism / Proteolytic breakdown, not CYP; very low CYP inhibition or induction potential [1]
- Bupropion metabolism / Mainly CYP2B6 to hydroxybupropion; inhibits CYP2D6 [3][2]
- Shared absorption effect / Semaglutide slows gastric emptying; the Ozempic label reports no clinically relevant change in oral drug absorption [1]
- Bupropion seizure risk / About 0.1% with sustained release up to 300 mg/day; about 0.4% (13 of 3,200) with immediate release at 300 to 450 mg/day [2]
- Bupropion boxed warning / Suicidal thoughts and behaviors, antidepressant class warning [3]
- Semaglutide suicidality warning / None in the current Ozempic label or the Rybelsus/Ozempic tablets label [1][4]
Is there a direct interaction between Ozempic and bupropion?
The Ozempic label's drug interactions section covers two topics: insulin secretagogues and insulin, where the concern is hypoglycemia, and oral medications in general, where the concern is delayed gastric emptying. It does not name bupropion or any antidepressant [1]. The interaction highlights of the Contrave label, which contains bupropion, cover MAO inhibitors, opioids, CYP2D6 substrates, digoxin, CYP2B6 inhibitors and inducers, other drugs that lower the seizure threshold, levodopa and amantadine, and urine drug screens. No GLP-1 receptor agonist appears there [3].
Semaglutide is a peptide. The label describes breakdown by proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain, not by CYP enzymes, plus very low potential to inhibit or induce CYP enzymes [1]. Bupropion is handled by CYP2B6, which converts it to hydroxybupropion [3], and it inhibits CYP2D6. That inhibition matters for other drugs: in 15 CYP2D6 extensive metabolizers, bupropion 150 mg twice daily raised desipramine AUC about 5-fold, and the effect lasted at least 7 days after the last bupropion dose [2].
What people on Reddit report
Personal accounts from people taking semaglutide and bupropion together. Experiences vary, and none of them are clinical data.
I take both. No issues for me, although I do take the bupropion in the early mornings and my shot after 2:00 p.m. on the days that I need to dose myself, just to be extra cautious.Read the source discussion
Yes, people take Contrave and Ozempic simultaneously, and, it's commonly done when one alone is no longer enough. Sounds like you're in good hands.Read the source discussion
Does Ozempic change how bupropion is absorbed?
Semaglutide delays gastric emptying. The Ozempic label says this has the potential to affect the absorption of oral medications, but that in clinical pharmacology trials semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree. The label still says caution should be exercised with oral medications [1].
An effect was measured with the oral semaglutide tablets: levothyroxine exposure rose 33% [4]. Bupropion was not among the drugs the labels report testing.
Seizure risk with bupropion: what the label says
Bupropion's seizure risk is dose-related. The Zyban label gives about 0.1% (1 in 1,000) with sustained-release bupropion up to 300 mg/day and about 0.4% (13 of 3,200) with immediate-release bupropion at 300 to 450 mg/day; for the immediate-release form the estimated incidence rises almost tenfold between 450 and 600 mg/day [2]. Labeled daily maximums are 400 mg for Wellbutrin SR, 300 mg for the smoking-cessation product, and 450 mg for immediate release [2].
The label's list of factors that add risk includes severe head injury, CNS tumor or infection, severe stroke, hypoglycemia, hyponatremia, severe hepatic impairment, diabetes treated with insulin or oral drugs, heavy alcohol use, cocaine and other illicit drugs, misuse of CNS stimulants, and other drugs that lower the seizure threshold [2]. The label says to stop bupropion and not restart it after a seizure [2].
Wellbutrin XL is contraindicated in seizure disorder; current or prior bulimia or anorexia nervosa; abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs; use with an MAO inhibitor intended to treat psychiatric disorders, or within 14 days of stopping one; starting it in a patient on a reversible MAOI such as linezolid or intravenous methylene blue; and known hypersensitivity to bupropion [3]. The labels also call for at least 14 days after stopping bupropion before starting an MAOI antidepressant [3].
One item on the seizure risk list overlaps with semaglutide's label. Hypoglycemia is a listed bupropion seizure risk factor [2], and Ozempic raises hypoglycemia risk when used with insulin or a sulfonylurea: documented symptomatic low glucose occurred in 29.8% of patients on Ozempic 1 mg with basal insulin versus 15.2% on placebo [1].
Nausea, vomiting and fluid loss on the semaglutide side
Gastrointestinal effects are the common ones for semaglutide. In pooled placebo-controlled Ozempic trials in type 2 diabetes, nausea occurred in 15.8% on 0.5 mg and 20.3% on 1 mg versus 6.1% on placebo, and any GI reaction in 32.7% and 36.4% versus 15.3% [1].
The label describes postmarketing reports of acute kidney injury, in some cases requiring dialysis, mostly in patients who had nausea, vomiting or diarrhea leading to dehydration. It asks for renal function monitoring in anyone with reactions that could cause volume depletion, especially during dose initiation and escalation [1]. The label also says to discontinue Ozempic if pancreatitis is suspected [1].
Mood and suicidality warnings
Bupropion carries a boxed warning for suicidal thoughts and behaviors, the antidepressant class warning, and it applies to every bupropion product, including those labeled for smoking cessation or weight management. The warning describes increased risk in children, adolescents and young adults in short-term trials and asks for close monitoring of patients of all ages [3].
Semaglutide's labels read differently. The current Ozempic label and the Rybelsus/Ozempic tablets label do not include a suicidal behavior and ideation warning [1][4].
What the labels say to monitor
The Contrave label, which contains bupropion, says to monitor blood pressure and heart rate in all patients, especially those with cardiac or cerebrovascular disease. It also lists angle-closure glaucoma in people with untreated narrow angles, and allergic reactions including anaphylaxis and Stevens-Johnson syndrome [3].
The Ozempic label's monitoring requests center on volume depletion, kidney function and pancreatitis, as above [1]. It recommends no dose adjustment for renal or hepatic impairment [1].
A small pharmacokinetic study adds one consideration that belongs to bupropion alone: in six elderly patients with depression, mean bupropion half-life was 34.2 hours and clearance was about 80% of the value reported for younger patients [7].
Questions worth asking
What the labels do not cover
The labels contain no data on bupropion blood levels during semaglutide treatment, or on the two drugs compared or combined for weight, mood or seizure outcomes. The picture here rests on each drug's own label.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Can you take Ozempic and bupropion together?
Does Ozempic change bupropion levels?
Does bupropion raise seizure risk more when taken with Ozempic?
Is Wellbutrin XL handled differently from other bupropion with Ozempic?
Does bupropion make Ozempic less effective?
What do the labels say to monitor with each drug?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Can I take bupropion while on Ozempic?
Neither the Ozempic label nor the Contrave label describes an interaction between the two, so the labels give no specific guidance on taking them together. Bupropion's own main safety issue is dose-related seizure risk, about 0.1% with sustained release up to 300 mg/day and about 0.4% with immediate release at 300 to 450 mg/day. The labels contain no data on the two drugs given together.
What should you not mix with bupropion?
Bupropion should not be combined with an MAO inhibitor intended to treat psychiatric disorders, or started within 14 days of stopping one, and the labels also call for at least 14 days after stopping bupropion before starting an MAOI antidepressant. Wellbutrin XL is also contraindicated in seizure disorder, current or prior bulimia or anorexia nervosa, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs. Heavy alcohol use and cocaine also raise seizure risk.
What is the dark side of Wellbutrin?
The main serious warning is a boxed warning for suicidal thoughts and behaviors, the antidepressant class warning, which applies to every bupropion product. It describes increased risk in children, adolescents and young adults in short-term trials and asks for close monitoring of patients of all ages. Seizure risk is also dose-related, about 0.4% with immediate release at 300 to 450 mg/day.
References
Show all 9 referencesHide references
- U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
- U.S. Food and Drug Administration. Zyban (bupropion hydrochloride) prescribing information. Zyban label
- U.S. National Library of Medicine, DailyMed. Contrave Extended-Release (naltrexone and bupropion), Azurity (naltrexone hydrochloride and bupropion hydrochloride) prescribing information. Contrave Extended-Release (naltrexone and bupropion), Azurity (naltrexone hydrochloride and bupropion hydrochloride) label
- U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
- Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35(9):876-84.
- Reddit participants. Wellbutrin/Bupropion and Ozempic (r/Ozempic). Accessed 2026-11-10.
- Reddit participants. [deleted by user] (r/Ozempic). Accessed 2026-11-10.